Bayer flags major Phase III results for stroke prevention drug asundexian
The study evaluated asundexian (50 mg), a once-daily oral anticoagulant candidate, versus placebo—both given alongside standard antiplatelet therapy
The study evaluated asundexian (50 mg), a once-daily oral anticoagulant candidate, versus placebo—both given alongside standard antiplatelet therapy
Backed by funding from an NIHR Doctoral Award, the guidance is focused on spotting abdominal tumours
A major highlight of the event was the launch of several publications and digital initiatives, including a certification course on the Ayush Grid portal
Backed by a £680,000 grant from Leeds Hospitals Charity, the study is jointly led by academics and clinicians from the University of Leeds and Leeds Teaching Hospitals NHS Trust
These results were consistent across all clinically relevant patient subgroups regardless of key patient characteristics like age or sex, the cause of stroke or the severity of the stroke
This license is a key regulatory milestone in advancing Hester's prevention-led poultry healthcare portfolio
Blood tests measuring biomarkers such as p-tau217 are emerging as accurate, accessible alternatives
The SNS records neural activity from 60 channels across four brain regions—far exceeding current commercial devices
The clearance for TELLTALE positions Transmural Systems at the forefront of next-generation electrosurgical solutions for structural heart interventions
The fresh capital will propel Cordance into its first-in-human clinical trial
Subscribe To Our Newsletter & Stay Updated